Brian D Athey

This inventor holds 8 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: University of Michigan. Active years: 2019-2025.

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 36(Granted Patents)

Location History:

Ypsilanti, MI (US) (2021)
Ann Arbor, MI (US) (2019 - 2024)

Company Filing History:

8 out of 3,523

University of Michigan

patents

Years Active: 2019-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12211601 - Methods and system for the reconstruction of drug response and disease networks and uses thereof (2025-01-28),

2. 12176087 - Pharmacogenomic decision support for modulators of the NMDA, glycine, and AMPA receptors (2024-12-24),

3. 12154661 - Method and apparatus for analysis of chromatin interaction data (2024-11-26),

4. 11984208 - Methods and system for the reconstruction of drug response and disease networks and uses thereof (2024-05-14),

5. 10915729 - Three-dimensional cell and tissue image analysis for cellular and sub-cellular morphological modeling and classification (2021-02-09),

6. 10867702 - Individual and cohort pharmacological phenotype prediction platform (2020-12-15),

7. 10553318 - Individual and cohort pharmacological phenotype prediction platform (2020-02-04),

8. 10249389 - Individual and cohort pharmacological phenotype prediction platform (2019-04-02),

Title: Brian D Athey: Innovator in Pharmacogenomics

Introduction

Brian D Athey is a prominent inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of pharmacogenomics, holding a total of 8 patents. His work focuses on the intersection of artificial intelligence and drug response, aiming to improve clinical decision-making and patient outcomes.

Latest Patents

Among his latest patents is a groundbreaking method and system for the reconstruction of drug response and disease networks. This innovative approach utilizes an integrated, multiscale artificial intelligence-based system to reconstruct drug-specific pharmacogenomic networks. The system leverages features of the functional topology of three-dimensional architecture in chromatin space, allowing for the discovery of drug pharmacogenomic networks through advanced techniques such as machine learning and deep learning. Another notable patent involves pharmacogenomic decision support for patients diagnosed with treatment-resistant conditions, providing personalized recommendations for medication and dosage based on genetic factors.

Career Highlights

Brian D Athey is affiliated with the University of Michigan, where he continues to advance research in pharmacogenomics. His work has the potential to transform how clinicians approach treatment for various conditions, particularly in identifying the most effective therapies for individual patients.

Collaborations

He has collaborated with notable colleagues, including Alex S Ade and Alexandr Kalinin, contributing to a rich environment of innovation and research.

Conclusion

Brian D Athey's contributions to pharmacogenomics exemplify the impact of innovative thinking in medicine. His patents and research are paving the way for more personalized and effective treatment options for patients.